miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

Maria Teresa Di Martino; Mariamena Arbitrio; Daniele Caracciolo; Alessia Cordua; Onofrio Cuomo; Katia Grillone; Caterina Riillo; Giulio Caridà; Francesca Scionti; Caterina Labanca; Caterina Romeo; Maria Anna Siciliano; Maria D'Apolito; Cristina Napoli; Martina Montesano; Valentina Farenza; Valentina Uppolo; Michele Tafuni; Federica Falcone; Giuseppe D'Aquino; Natale Daniele Calandruccio; Francesco Luciano; Licia Pensabene; Pierosandro Tagliaferri; Pierfrancesco Tassone

doi:10.1016/j.omtn.2022.02.005

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

Mol Ther Nucleic Acids. 2022 Feb 11:27:1191-1224. doi: 10.1016/j.omtn.2022.02.005. eCollection 2022 Mar 8.

Authors

Maria Teresa Di Martino¹, Mariamena Arbitrio², Daniele Caracciolo¹, Alessia Cordua¹, Onofrio Cuomo¹, Katia Grillone¹, Caterina Riillo¹, Giulio Caridà¹, Francesca Scionti³, Caterina Labanca¹, Caterina Romeo¹, Maria Anna Siciliano¹, Maria D'Apolito¹, Cristina Napoli¹, Martina Montesano¹, Valentina Farenza¹, Valentina Uppolo¹, Michele Tafuni¹, Federica Falcone¹, Giuseppe D'Aquino¹, Natale Daniele Calandruccio¹, Francesco Luciano¹, Licia Pensabene⁴, Pierosandro Tagliaferri¹, Pierfrancesco Tassone¹

Affiliations

¹ Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
² Institute for Research and Biomedical Innovation (IRIB), Italian National Council (CNR), Catanzaro, Italy.
³ Institute for Research and Biomedical Innovation (IRIB), Italian National Council (CNR), Messina, Italy.
⁴ Department of Surgical and Medical Sciences, Magna Græcia University, Catanzaro, Italy.

Abstract

Among deregulated microRNAs (miRs) in human malignancies, miR-221 has been widely investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence suggests miR-221 as a fine-tuner of chronic liver injury and inflammation-related events. Available information also supports the potential of miR-221 silencing as promising therapeutic intervention. In this systematic review, we selected papers from the principal databases (PubMed, MedLine, Medscape, ASCO, ESMO) between January 2012 and December 2020, using the keywords "miR-221" and the specific keywords related to the most important hematologic and solid malignancies, and some non-malignant diseases, to define and characterize deregulated miR-221 as a valuable therapeutic target in the modern vision of molecular medicine. We found a major role of miR-221 in this view.

Keywords: NASH; biliary tract cancer; bladder cancer; breast cancer; cancer; cervical cancer; demyelinating diseases; endometrial cancer; gastrointestinal cancer; glioblastoma; gynecological cancers; hematological diseases; hepatocellular carcinoma; lung cancer; melanoma; miR; miR therapeutics; miR-221; miR-221/222; miRs; microRNA; myeloma; neuropathy; ovarian cancer; pancreatic cancer; pharmacokinetics; prostate cancer; renal cell carcinoma; sarcomas; solid cancers; urogenital cancer.

Publication types

Review